Question? Call us
212-363-7500Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Tempus AI, Inc. made materially false and/or misleading statements and/or failed to disclose that: Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company. Among other issues, the Spruce Point report asserted that the Company used "aggressive accounting and financial reporting"; that several members of the Company's Board and "other executives have been associated with troubled companies that restated financial results"; and that "[k]ey strategic partnerships and deal announcement[s] with AstraZeneca and Pathos AI merit scrutiny." Following this news, Tempus's stock price fell sharply during intraday trading on the same day.
In order to be eligible to join the TEM class action lawsuit, you must have incurred a loss on shares of Tempus AI, Inc. purchased during the class period listed above.
TOP